**Página de título**

**Title of the article (EN)- Late-night Salivary Cortisol: cut-off definition and diagnostic value for Cushing’s Syndrome in a Portuguese population**

**Título do artigo (PT)- Cortisol Salivar Noturno: definição de ponto de corte e valor diagnóstico na Síndrome de Cushing numa população Portuguesa**

**Autores:**

- Dr. Adriana De Sousa Lages; Endocrinology, Diabetes and Metabolism Department, Coimbra Hospital and University Center; Coimbra, Portugal

- Dr. João Gonçalo Frade; Clinical Pathology Department, Coimbra Hospital and University Center; Coimbra, Portugal; School of Health Sciences, Polytechnic Institute of Leiria, Portugal

- Dr. Diana Oliveira; Endocrinology, Diabetes and Metabolism Department, Coimbra Hospital and University Center; Coimbra, Portugal

- Dr. Isabel Paiva; Endocrinology, Diabetes and Metabolism Department, Coimbra Hospital and University Center; Coimbra, Portugal

- Dr. Patrícia Oliveira; Endocrinology, Diabetes and Metabolism Department, Coimbra Hospital and University Center; Coimbra, Portugal

- Dr. Alexandre Rebelo-Marques; Family Health Unit from Condeixa, ACeS Baixo Mondego, ARS Centro; Faculty of Medicine of the University of Coimbra, Portugal

- Dr. Francisco Carrilho; Endocrinology, Diabetes and Metabolism Department, Coimbra Hospital and University Center; Coimbra, Portugal

**Autor responsável:**

Adriana De Sousa Lages

Endereço: Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal

E-mail: adrianamslages@gmail.com; Contato telefónico: +351912244162

**Título breve para cabeçalho:** Late-night Salivary Cortisol for the diagnosis of Cushing’s Syndrome

**Contagem de palavras:** 3035

**Tipo de artigo:** Artigo Original

**Subsídio(s) ou bolsa(s) que contribuíram para a realização do trabalho:** os autores não usufruíram de qualquer subsídio ou bolsa para realização do trabalho.

**2ª página**

**Title of the article (EN)- Late-night Salivary Cortisol: cut-off definition and diagnostic value for Cushing’s Syndrome in a Portuguese population**

**Título do artigo (PT)- Cortisol Salivar Noturno: definição de ponto de corte e valor diagnóstico na Síndrome de Cushing numa população Portuguesa**

**Resumo:**

Introdução: O diagnóstico de Síndrome de Cushing continua a ser um desafio complexo. O cortisol salivar noturno é utilizado como teste de rastreio, contudo, a definição de um valor diagnóstico deverá ser individualizada.

Materiais e métodos: Foram estudados 3 grupos: voluntários saudáveis, com suspeita clínica e com diagnóstico estabelecido de Síndrome de Cushing. Doseamento de Cortisol Salivar foi realizado por eletroquimioluminescência automatizado. A definição do ponto-de-corte foi obtida pela curva *Receiver Operating Characteristic* (ROC) e índice *Youden (J).*

Resultados: Entre os 127 indivíduos, 57 pertenciam ao grupo de voluntários saudáveis, 39 com suspeita clínica e 31 com diagnóstico estabelecido. O percentil 2.5 - 97.5 de cortisol salivar noturno no grupo de voluntários saudáveis foi 0.054 - 0.1827μg/dL. A análise da curva de ROC revelou uma área abaixo da curva de 0.9881 (p<0.0001) e o ponto-de-corte de 0.1 μg/dL com sensibilidade de 96.77% e especificidade de 91.23%. Verificou-se uma correlação significativa entre cortisol salivar noturno e o cortisol sérico noturno (R=0.6977; p<0.0001), bem como, com cortisol livre urinário (R=0.5404; p 0.0025) no grupo com diagnóstico estabelecido.

Discussão: A concentração média ± DP cortisol salivar noturno no grupo com diagnóstico estabelecido (0.6798±0.52μg/dL) foi significativamente superior aos restantes grupos. Na nossa população, o valor de ponto-de-corte foi de 0.1 μg/dL com elevada sensibilidade e especificidade.

Conclusões: Os resultados demonstram uma excelente acurácia do cortisol salivar noturno. Dada a sua conveniência e elevada exatidão, o doseamento de cortisol salivar noturno poderá ser proficuamente adicionado aos testes de rastreio tradicionais para estudo de hipercortisolismo.

**Abstract:**

Background: Diagnosis of Cushing’s syndrome remains a challenge in clinical endocrinology. Late-night salivary cortisol is used as screening tool, however, individualized cut-off levels for each population must be defined.

Methods: Three group of subjects were studied: normal subjects, suspected and proven Cushing’s syndrome. Salivary Cortisol was measured using an automated electrochemiluminescence assay. The functional sensitivity of the assay is 0.018 μg/dL. Diagnostic cut-off level was defined by Receiver operating characteristic (ROC) curve and Youden’s J index.

Results: We studied 127 subjects: 57 healthy volunteers, 39 patients with suspected and 31 with proven Cushing’s syndrome. 2.5th - 97.5th percentile of the late-night salivary cortisol concentrations in normal subjects was 0.054 to 0.1827μg/dL. ROC curve analysis showed an area under the curve of 0.9881 (p<0.0001). A cut-off point of 0.1 μg/dL provided a sensibility of 96.77% (95%CI 83.3-99.92%) and specificity of 91.23% (95%CI 80.7-97.09%). There was significant correlation between late-night salivary cortisol and late-night serum cortisol (R=0.6977; p<0.0001) and urinary free cortisol (R=0.5404; p 0.0025) in proven Cushing’s syndrome group.

Discussion: The mean ± SD late-night salivary cortisol concentration in patients with proven Cushing’s syndrome (0.6798±0.52μg/dL) was significantly higher (p<0.0001). In our population, the late-night salivary cortisol cut-off was 0.1 μg/dL with high sensitivity and specificity.

Conclusion: Our results associate late-night salivary cortisol with an excellent accuracy and reaffirm that can be used as a highly reliable, noninvasive, screening tool for outpatient assessment. Given its convenience and diagnostic accuracy, late-night salivary cortisol may be profitably added to other traditional screening tests on hypercortisolism**.**

**Palavras-chave (*Keywords*):** Cortisol; Salivary; Cushing; Diagnosis; Late-night

**Original article:**

**Introduction:**

Considering the increasing worldwide prevalence of metabolic syndrome, there is a growing need to effectively screen effectively patients for secondary causes of obesity, namely endocrine causes, as Cushing’s Syndrome (CS).1 However, the diagnosis of CS remains a demanding challenge in clinical endocrinology.

An ideal screening test should be specific enough to avoid false positives, in order to minimize their associated cost and morbidity, and sensitive enough to classify as positives those persons with the disease.2

The latest Endocrine Society clinical practice guidelines on the diagnosis of CS recommend the use of one from four screening tests: 24-hours urinary free cortisol (UFC) - at least two measurements, 1mg overnight dexamethasone suppression test (DST), late-night salivary cortisol (LNSaC) -two measurements- and longer low-dose DST (2mg/day for 48hours) as initial screening tests.3

The lack of invasiveness, convenience and simplicity of the LNSaC justify a growing interest on applying it to a wide range of patients on clinical daily practice and has been used recently by many centres as a first line diagnostic test for CS.

The definition of the LNSaC cut-off level is highly dependent on the performance of the laboratory assay used: radioimmunoassay (RIA), automated electrochemiluminescence immunoassays (ECLIAs) or, more recently, liquid chromatography-tandem mass spectrometry (LC-MS/MS).4-12

Moreover, the need to define an individualized cut-off level for each population motivated our study since there is only one published study from Portugal using RIA.13

Therefore, our goals were to compare the LNSaC functional capacity, measured by an ECLIA assay, with other screening tests as 24-h UFC and late-night serum cortisol (LNSeC); to establish the reference range for LNSaC concentration in a Portuguese population sample, as well as, to evaluate its usefulness in the diagnosis of CS.

**Subjects and Methods:**

Subjects

The study was conducted in the Endocrinology Department inpatient clinic of a tertiary Portuguese hospital centre. Patients were enrolled from July 2014 to August 2016. Data were collected from patients with clinical suspicion of hypercortisolism at ward admission. All participants gave written informed consent to participate in the study.

Three groups of subjects were enrolled: (a) normal healthy individuals and (b) patients attending the inpatient clinic with ages between 18-65 years who were either (b1) either referred for suspected hypercortisolism on the basis of clinical features or with discordant ambulatory screening tests results or (b2) proven to have CS based on laboratory and histology findings.

Normal subjects

Normal subjects (or control/healthy group) were studied to establish the LNSaC reference range for the utilized assay.

Medical and paramedical professionals from the Endocrinology Department and Clinical Pathology Department as well as patients from a primary care setting on a local Family Health Unit were invited to participate.

All the subjects included on the control group answered a brief questionnaire about past medical history and current medication. They were asymptomatic, apparently healthy and with regular menses (in the case of pre-menopausal women).

We excluded volunteers who fulfilled the following criteria: other known endocrine condition (as diabetes mellitus, thyroid disease or polycystic ovary syndrome); chronic pain condition; alcoholism; active smoking; pregnancy; chronic kidney or liver disease; psychiatric illness; shift workers and on current medical therapy with levothyroxine, glucocorticoids (including topic and nasal formulations), insulin and anticonvulsivants.

Patients with proven CS

For patients with at least one abnormal screening tests or for whom the pre-test probability was high, an inpatient evaluation was scheduled to repeat the abnormal test previously performed and complement the evaluation with a cortisol circadian rhythm (serum cortisol and adrenocorticotrophin hormone (ACTH) levels at 23/00h and 8/9h), longer low-dose DST or CRH test. The aetiological diagnosis of CS was based on plasma ACTH concentration which, guided the imagiological evaluation. An ACTH >20 pg/mL with concomitant increased serum cortisol was considered suggestive of ACTH-dependent CS and subsequently justified a CRH test. An elevation of at least 50% in ACTH and 20% in cortisol after CRH infusion was suggestive of pituitary source and justified a pituitary imaging. If an ectopic source was suspected, especially with highly elevated levels of ACTH with no response on CRH test, a thoracic/abdominal image was performed by MRI or CT scan or also by positron emission tomography (PET) scan in rarer cases. On contrary, an ACTH<5 pg/mL associated with an elevated cortisol level was suggestive of ACTH-independent CS source and led to adrenal investigation. 3,14

The patients included in the “proven CS” group were patients submitted to surgical intervention and with histological findings confirming CS diagnosis.

Patients with suspected CS

Subjects included on the “suspected CS” group were referred to the Endocrinology Department due to clinical manifestations (visceral obesity, diabetes or glucose intolerance, hypertension, menstrual irregularities, low bone density) or presence of signs/symptoms highly suggestive of hypercortisolism (purple striae, ecchymoses or proximal myopathy) with, at least, one abnormal positive screening test.

Patients undergoing investigation due to the presence of adrenal or pituitary incidentalomas were also included in this group.

The diagnosis of CS was not confirmed after additional inpatient investigation in these patients.

Saliva collection and storage

Participants collected saliva samples between 11 PM and midnight on non-working days using a cylindrical cotton swab (provided as a standard device called Salivette©). Written recommendations were delivered for each participant along with a written participation consent.

Absence of physical exercise for at least 3 hours before sample collection, delicate teeth brushing and avoidance of cigarette smoking on the day of sampling was advised. It was explained to the participants that they should gently chew the cotton inside the Salivette© device for 2 to 3 minutes.

When collected at home, the devices were stored at room temperature until delivery to the investigator on the next day and then directly to the laboratory.

For patients evaluated during hospitalization, samples were collected on the second and third day at the ward and sent to the laboratory on the next morning.

Samples were centrifuged at 2000-2500 rpm for 3 to 5 min, the cotton swab removed, and the clear effluent stored at -20ºC until assayed by the same laboratory technician.

Only 50 μl of saliva were required for the analysis.

Laboratory Assay

Salivary cortisol was measured by automated ECLIA on a Roche© Elecsys 2010 automated analyser, a competitive polyclonal antibody immunoassay that employs a magnetic separation step followed by electrochemiluminescence quantitation. The cortisol in the biological sample is detached from the cortisol-binding globulin by danazol. The detached cortisol competes with the ruthenium-labelled cortisol tracer for the cortisol antibody, which is attached to biotin in a second step.

The assay takes a total of 18 minutes to run and the measuring range of the assay is 0.018-63.4 μg/dL (0.5 - 1750 nmol/L). The reported functional sensitivity of the assay reported is <0.308 μg/dL (<8.5 nmol/L).

The salivary cortisol normal reference range, provided by the manufacturer and determined in samples from 154 healthy individuals, was: 8 AM-10 AM: <0.69 μg/dL (<19.1 nmol/L); 2:30 PM- 3:30 PM: <0.43 μg/dL (<11.9 nmol/L).15

The following cross-reactivities were also referred by Roche© : corticosterone – 5.8%, 11-deoxycortisol – 4.1%, 17-α-hydroxyprogesterone – 1.5%, prednisone – 0.28% and dexamethasone – 0.08%.

Statistical analysis

Salivary cortisol concentrations below the assay’s detection limit were set to the limit value. Quantitative parameters are presented as mean ± SD or median (range: minimum-maximum) and qualitative parameters are presented as percentages and binomial 95% confidence intervals. LNSaC concentrations obtained from the normal healthy volunteers were used to define the lower (2.5th percentile) and upper (97.5th percentile) limits of the reference range.

Comparison of continuous variables among groups was performed using Student’s t -test and bivariate correlations between variables using Pearson correlation test.

Spearman’s rank order test was used to check the correlation of cortisol concentrations in different samples - serum, saliva and urinary specimens.

The diagnostic cut-off level was defined using the receiver operating characteristic (ROC) curve. The LNSaC concentration with highest sensitivity and specificity was calculated by Youden’s J index.16

Statistical analysis was performed with IBM SPSS Statistics V.24 (Chicago, IL, USA) software for Mac. Values of p<0.05 were considered statistically significant.

**Results:**

A total of one hundred twenty-seven individuals were enrolled in the study and were divided in 3 distinct groups: 57 in “normal subjects” group; 39 in the “suspected CS” group and 31 in the “proven CS” group. The last group included 24 patients with ACTH-dependent CS (22 from pituitary origin and 2 from an ectopic source of pulmonary origin) and 7 patients with ACTH-independent hypercortisolism (2 adrenal adenomas and 5 adrenal carcinomas)- (Figure 1 and Table 1).

Anthropometric and demographic characteristics for all participants are summarized in Table 1. All of the participants were caucasian and originally from Portugal.

Mean age was comparable among the three study groups and a preponderance of female participants was a common denominator.

Regarding BMI, the results were similar between the “suspected CS” and “proven CS” groups (30.23±6.4 and 30.74±5.62 kg/ m2, respectively); however, patients in control group had slightly lower BMI (24.71±4.18 kg/m2).

The mean ± SD LNSaC concentration in patients from “proven CS” group (0.6798±0.52μg/dL) was significantly higher compared with those in “normal subjects” (0.0642± 0.03μg/dL; p<0.0001) and “suspected CS” group (0.1803± 0.19 μg/dL; p<0.0001) (Table 1).

The 2.5th- 97.5th percentile of the LNSaC concentrations obtained from the “normal subjects” group was 0.054 to 0.1827 μg/dL creating our specific population reference range (Table 1).

A positive significant correlation was found between the LNSaC and LNSeC levels (R=0.6977; p<0.0001) as well as with UFC in “proven CS” group (R=0.5404; p=0.0025). Using a linear regression model, there is a positive association between LNSaC and LNSeC as well as with UFC (Figure 2).

The ROC curve was created to establish the optimal threshold diagnostic LNSaC value and to evaluate the overall performance of salivary cortisol levels on CS diagnosis, including normal subjects and patients with proven diagnosis of CS. The Youden-J Index was calculated for the selection of the optimal cut-off point with higher sensibility (S) and specificity (E)- (Figure 3).

ROC curve analysis of LNSaC showed an AUC of 0.9881 (p<0.0001, 95% CI 0.9733 to 1.003). On the basis of this curve, the LNSaC cut-off point above which points to a glucocorticoid inappropriate secretion was of 0.1 μg/dL (2.76 nmol/L). This cut-off point gave the best diagnostic accuracy providing a S of 96.77% (95% CI 83.3-99.92%) and E of 91.23% (95% CI 80.7-97.09%)- (Figure 3). A cut-off value of 0.196 μg/dL (5.41 nmol/L) increases the specificity to 100% but lowers the sensitivity to 83.87%. Indeed, all the individuals included in the “normal subjects” group had LNSaC concentrations below this cut-off.

**Discussion:**

A normal sleep-wake cycle in a healthy person is characterized by a rising of serum cortisol level beginning in the early-morning (3-4 AM), reaching a peak at 7-9 AM and a decrement afterwards, reaching a nadir at midnight in an asleep person.17

Salivary Cortisol (SaC) measurement offers an evaluation of unbound circulating cortisol fraction since cortisol-binding globulin (CBG) is absent from saliva. Its independence from CBG levels, allows an evaluation not affected by changes related to oestrogen therapy, pregnancy or liver disease.18,19

Besides that, the measurement is not influenced by saliva flow rate. The general recommendation is to collect a saliva sample by passive drooling or by chewing a cotton device (usually, Salivette©) on two separate evenings at bedtime, between 11 PM-00 AM. The saliva sample is stable at room temperature and can be mailed directly to the laboratory by the patient. Within this line, this test offers a sensible non-invasive option, not requiring hospitalization and can be easily performed by the patient on a quiet evening at home.20

The usefulness of LNSaC has been reported in several studies but diagnostic cut-off levels are highly dependent on the laboratory assay used.4,5,7,9-12,19,21-32 Nevertheless, the discriminating power diminishes in the elderly population and tends to increase in presence of cardiovascular comorbidities as hypertension and diabetes.33

Moreover, several different factors should be considered on SaC levels interpretation. Persons using liquorice or chewing tabaco have conditioned expression of 11 β-hydroxysteroid dehydrogenase type 2 (11 β-HSD2) by the salivary glands and may have falsely elevated SaC values. Even in patients who smoke tobacco cigarettes, an elevated LNSaC is found comparing with non-smokers. This known fact supports the recommendation to avoid cigarette smoking on the day of sample collection.34,35

A possible contamination by a steroid-containing topic or oral agent will predictably falsely increase the SaC level obtained by cross-reaction and this should be excluded on a patient under investigation. Blood contamination from an oral injury might also falsely elevate SaC levels, so vigorous tooth brushing is strongly discouraged near sample saliva collection even with a minor impact expected by leakage.36

In patients who are shift-workers or constant travellers, an abnormal circadian rhythm is assumed and it is recommended that the time of sample collection may be re-adjusted to the usual bedtime, even if it is after midnight.3

In this study, using an ECLIA assay, we found a LNSaC reference range on “normal subjects” between <0.054 to 0.189 μg/dL.

The mean ± SD LNSaC concentration in patients with proven CS (0.6798±0.52μg/dL) was significantly higher than those in normal subjects (0.0642±0.03μg/dL; p<0.0001) and suspected CS group (0.1803±0.19 μg/dL; p<0.0001).

There were no statistically significant differences between groups regarding body mass index although the mean BMI was slightly higher in “Proven CS” group compared to the other two groups. This fact excludes a potential bias of body weight differences on LNSaC levels related to a higher 11 β-hydroxysteroid dehydrogenase type 1 activity on visceral fat which promotes the conversion of cortisone to active cortisol.

ROC curve analysis showed an AUC of 0.9881 (p<0.0001). A cut-off point of 0.1 μg/dL provides a S of 96.77% (95%CI 83.3-99.92%) and E of 91.23% (95%CI 80.7-97.09%). Besides that, we also found significant correlations between LNSaC and late-night serum cortisol (LNSeC) levels (r=0.6977; p<0.0001) as well as with UFC levels (r=0.5404; p 0.0025) in proven CS group. Therefore, the significant correlation between LNSaC and other classical screening tests on hypercortisolism reaffirms the quality requirements of its use as a reliable test (Figure 2).

Other published studies using ECLIA show a large variability regarding reference ranges in healthy subjects, emphasizing the need of each laboratory to establish its own reference range and cut-off criteria.4,5,8,11,28,32,37 The majority of studies published use radioimmunoassay for measuring salivary cortisol, including the only published data on a Portuguese population, which found a clearly large reference range for LNSaC (1.0-14.9nmol/L; 0.036-0.54 μg/dL).13 On the other hand, the Endocrine Society practice guidelines recommend a cut-off point of 0.14 μg/dL (4 nmol/l) based on ELISA and LC-MS/MS assays which are considered the best validated assays used in the USA for measuring LNSaC. This cut-off value is close to the value of 0.1 μg/dL we propose in our study.

The main advantage of automated ECLIA technique, comparing to radioimmunoassay, is to allow results on the same day that samples are delivered to the laboratory (within 20 minutes) with good analytical performance, providing precious information to the clinical team who follows the patient. Other benefits are related to the fact that samples need no pre-treatment and individual samples can be processed efficiently using this technique.

One of the strengths of our study is the inclusion of a normal population, mostly recruited from a Family Health Unit on primary care setting, to define the reference range for our laboratory assay. We carefully excluded potential bias that are known to falsely elevate LNSaC, such active smokers and shift workers.

However, one recognized limitation of our study is the low number of UFC and LNSeC samples collected from the same patient at the same time of LNSaC collection (Table 2). This fact may explain the scatter graph obtained with moderate, though significant, positive correlation found between tests (Figure 2). Another limitation of our study is related to the fact that saliva samples from “normal subjects” group were collected on a single occasion and not at least in two separate days, which could preclude the disclosure of a subtle cortisol excess condition. In contrast, all the patients who collected samples in ward, had two different samples in two different days after the first day of hospital admission.

**Conclusions:**

The LNSaC is a simple, convenient and non-invasive stress-free test which can be applied to a wide range of patients.

Our results give to LNSaC an excellent accuracy and reaffirm that this test can be used as a highly reliable, non-invasive, screening tool for outpatient assessment in agreement with previous studies.

The majority of studies published use radioimmunoassay for measuring salivary cortisol and even those using ECLIA show a large heterogeneity, so, an individualized cut-off and reference range is better established by each local laboratory.

In our population, the LNSaC reference cut-off was 0.1 μg/dL with sensitivity of 96.77% and specificity of 91.23% for Cushing’s Syndrome diagnosis. Given its convenience and diagnostic accuracy, LNSaC may be profitably added to other traditional screening tests on hypercortisolism, such as LNSeC and UFC.

**References:**

1. NRFC. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-42. Epub 2017/10/10. doi: 10.1016/s0140-6736(17)32129-3. PubMed PMID: 29029897; PubMed Central PMCID: PMCPMC5735219.

2. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65(4):281-393. PubMed PMID: 4234760.

3. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40. doi: 10.1210/jc.2008-0125. PubMed PMID: 18334580; PubMed Central PMCID: PMCPMC2386281.

4. Vogeser M, Durner J, Seliger E, Auernhammer C. Measurement of late-night salivary cortisol with an automated immunoassay system. Clin Chem Lab Med. 2006;44(12):1441-5. doi: 10.1515/cclm.2006.244. PubMed PMID: 17163820.

5. Yaneva M, Mosnier-Pudar H, Dugué MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab. 2004;89(7):3345-51. doi: 10.1210/jc.2003-031790. PubMed PMID: 15240613.

6. van Aken MO, Romijn JA, Miltenburg JA, Lentjes EG. Automated measurement of salivary cortisol. Clin Chem. 2003;49(8):1408-9. PubMed PMID: 12881461.

7. Doi M, Sekizawa N, Tani Y, Tsuchiya K, Kouyama R, Tateno T, et al. Late-night salivary cortisol as a screening test for the diagnosis of Cushing's syndrome in Japan. Endocr J. 2008;55(1):121-6. PubMed PMID: 18202529.

8. Shi SR, Gan W, Zhou XT, Xiong ZY, An ZM. [Diagnostic value of salivary cortisol in Cushing's syndrome]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40(2):298-301. PubMed PMID: 19462912.

9. Antonelli G, Ceccato F, Artusi C, Marinova M, Plebani M. Salivary cortisol and cortisone by LC-MS/MS: validation, reference intervals and diagnostic accuracy in Cushing's syndrome. Clin Chim Acta. 2015;451(Pt B):247-51. doi: 10.1016/j.cca.2015.10.004. PubMed PMID: 26449783.

10. Belaya ZE, Iljin AV, Melnichenko GA, Rozhinskaya LY, Dragunova NV, Dzeranova LK, et al. Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome. Endocrine. 2012;41(3):494-500. doi: 10.1007/s12020-012-9658-3. PubMed PMID: 22447310.

11. Carrozza C, Corsello SM, Paragliola RM, Ingraudo F, Palumbo S, Locantore P, et al. Clinical accuracy of midnight salivary cortisol measured by automated electrochemiluminescence immunoassay method in Cushing's syndrome. Ann Clin Biochem. 2010;47(Pt 3):228-32. doi: 10.1258/acb.2010.010020. PubMed PMID: 20406774.

12. Erickson D, Singh RJ, Sathananthan A, Vella A, Bryant SC. Late-night salivary cortisol for diagnosis of Cushing's syndrome by liquid chromatography/tandem mass spectrometry assay. Clin Endocrinol (Oxf). 2012;76(4):467-72. doi: 10.1111/j.1365-2265.2011.04239.x. PubMed PMID: 21955126.

13. Santos R, Prazeres S, Martins A, Sobrinho L. O valor do cortisol salivar em Endocrinologia Clínica. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo. 2010(02):31-40.

14. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-602. doi: 10.1210/jc.2003-030871. PubMed PMID: 14671138.

15. Cortisol, cat no. 11875116160 <https://dialog1.roche.com/us/en_us/eLabDoc> [cited 2018 February].

16. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654-7. doi: 10.1161/circulationaha.105.594929. PubMed PMID: 17283280.

17. Krieger DT, Allen W, Rizzo F, Krieger HP. Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab. 1971;32(2):266-84. doi: 10.1210/jcem-32-2-266. PubMed PMID: 4321505.

18. Tayek JA. Lower cortisol concentrations in patients with liver disease: more adrenal failure or more confusion? Crit Care Med. 2005;33(6):1431-2. PubMed PMID: 15942373.

19. Raff H. Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations. Endocrine. 2013;44(2):346-9. doi: 10.1007/s12020-013-0013-0. PubMed PMID: 23839587.

20. Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic--pituitary--adrenal axis activity. Clin Endocrinol (Oxf). 2005;63(3):336-41. doi: 10.1111/j.1365-2265.2005.02349.x. PubMed PMID: 16117823.

21. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab. 1998;83(8):2681-6. doi: 10.1210/jcem.83.8.4936. PubMed PMID: 9709931.

22. Putignano P, Dubini A, Toja P, Invitti C, Bonfanti S, Redaelli G, et al. Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol. 2001;145(2):165-71. PubMed PMID: 11454512.

23. Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab. 2003;88(9):4153-7. doi: 10.1210/jc.2003-030312. PubMed PMID: 12970280.

24. Trilck M, Flitsch J, Lüdecke DK, Jung R, Petersenn S. Salivary cortisol measurement--a reliable method for the diagnosis of Cushing's syndrome. Exp Clin Endocrinol Diabetes. 2005;113(4):225-30. doi: 10.1055/s-2005-837667. PubMed PMID: 15891959.

25. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Müller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab. 2005;90(10):5730-6. doi: 10.1210/jc.2004-2264. PubMed PMID: 16014408.

26. Arregger AL, Cardoso EM, Tumilasci O, Contreras LN. Diagnostic value of salivary cortisol in end stage renal disease. Steroids. 2008;73(1):77-82. doi: 10.1016/j.steroids.2007.09.001. PubMed PMID: 17945323.

27. Carroll T, Raff H, Findling JW. Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome. Nat Clin Pract Endocrinol Metab. 2008;4(6):344-50. doi: 10.1038/ncpendmet0837. PubMed PMID: 18446140.

28. Jeyaraman K, Ammini AC, Nandita G, Dwivedi SN. Late-night salivary cortisol in normal subjects and in patients with Cushing's syndrome. Postgrad Med J. 2010;86(1017):399-404. doi: 10.1136/pgmj.2009.090787. PubMed PMID: 20634249.

29. Raff H. Cushing's syndrome: diagnosis and surveillance using salivary cortisol. Pituitary. 2012;15(1):64-70. doi: 10.1007/s11102-011-0333-0. PubMed PMID: 21833616.

30. Elbuken G, Tanriverdi F, Karaca Z, Kula M, Gokahmetoglu S, Unluhizarci K, et al. Comparison of salivary and calculated free cortisol levels during low and standard dose of ACTH stimulation tests in healthy volunteers. Endocrine. 2015;48(2):439-43. doi: 10.1007/s12020-014-0378-8. PubMed PMID: 25115637.

31. Ryan R, Booth S, Spathis A, Mollart S, Clow A. Use of Salivary Diurnal Cortisol as an Outcome Measure in Randomised Controlled Trials: a Systematic Review. Ann Behav Med. 2016;50(2):210-36. doi: 10.1007/s12160-015-9753-9. PubMed PMID: 27007274; PubMed Central PMCID: PMCPMC4823366.

32. Kuzu I, Zuhur SS, Demir N, Aktas G, Yener Ozturk F, Altuntas Y. The diagnostic value of late-night salivary cortisol for diagnosis of subclinical Cushing's syndrome. Endokrynol Pol. 2016. doi: 10.5603/EP.a2016.0028. PubMed PMID: 26884297.

33. Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf). 2005;63(6):642-9. doi: 10.1111/j.1365-2265.2005.02395.x. PubMed PMID: 16343098.

34. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fukushima K, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81(9):3244-8. doi: 10.1210/jcem.81.9.8784076. PubMed PMID: 8784076.

35. Badrick E, Kirschbaum C, Kumari M. The relationship between smoking status and cortisol secretion. J Clin Endocrinol Metab. 2007;92(3):819-24. Epub 2006/12/19. doi: 10.1210/jc.2006-2155. PubMed PMID: 17179195.

36. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. Horm Behav. 2004;46(1):39-46. doi: 10.1016/j.yhbeh.2004.01.006. PubMed PMID: 15215040.

37. Beko G, Varga I, Glaz E, Sereg M, Feldman K, Toth M, et al. Cutoff values of midnight salivary cortisol for the diagnosis of overt hypercortisolism are highly influenced by methods. Clin Chim Acta. 2010;411(5-6):364-7. Epub 2009/12/05. doi: 10.1016/j.cca.2009.11.033. PubMed PMID: 19968981.

**Figures subtitles and tables:**

**Figure 1.** Late-night salivary cortisol concentrations in the three study groups. The dotted line (0.1 μg/dL) indicates the cut-off derived from the receiver operating characteristic curve.

**Figure 2.** Correlation between late-night serum cortisol (2a) and 24-h urinary free cortisol (UFC) excretion (2b) with late-night salivary cortisol in patients with proven Cushing Syndrome (CS).

**Figure 3.** Receiver operating characteristic curve of late-night salivary cortisol for the diagnosis of Cushing’s syndrome. Area under the curve 0.9881; p<0.0001.

**Table 1.** Clinical and biochemical profile of the three groups of subjects included; Abbreviations: BMI, body mass index; CS, Cushing’s syndrome; SD, standard deviation. \*p<0.05 vs the other two groups.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Normal subjects****(n=57)** | **Suspected CS****(n=39)** | **Proven CS****(n=31)** |
| **Age (years)****Mean±SD** | **47.9±11,09** | **51.54±18.00** | **46.19±14.11** |
| **Gender****Female****Male** | **35****22** | **25****14** | **27****5** |
| **BMI (kg/m2)****Mean±SD****Range** | **24.71±4.18****17.31-35.92** | **30.23±6.4****19.3-46.05** | **30.74±5.62****23.00-40.90** |
| **Salivary cortisol 23.00h (μg/dL)****Mean±SD****Median****Range****2.5% Percentile****97.5% Percentile** | **0.0642±0.03****0.054****0.054-0.189****0.054****0.1827** | **0.1803±0.19****0,109****0.054-0.851****0.054****0.851** | **0.6798 ±0.52\*****0.508****0.087-1.9****0.087****1.9** |

**Table 2.** Proven Cushing’s Syndrome group of patients: comparison between Late-night serum cortisol (LNSeC) and Urinary Free Cortisol (UFC).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Salivary Cortisol****11 PM/00 AM****(µg/dL)** | **Serum Cortisol****11 PM****(µg/dL)** | **UFC** **(µg/day)** |
| **Number of values** | **31** | **31** | **30** |
|  |  |  |  |
| **Minimum** | **0.054** | **1.31** | **2** |
| **25% Percentile** | **0.2133** | **3.355** | **46** |
| **Median** | **0.496** | **10.16** | **128** |
| **75% Percentile** | **1.053** | **18.55** | **343.3** |
| **Maximum** | **1.9** | **30.5** | **883** |
|  |  |  |  |
| **Mean** | **0.6603** | **12.07** | **220.2** |
| **Std. Deviation** | **0.5247** | **8.595** | **240.1** |
| **Lower 95% CI of mean** | **0.4711** | **8.966** | **130.6** |
| **Upper 95% CI of mean** | **0.8494** | **15.16** | **309.9** |